fbpx

Meropenem

CLASS

  • carbapenem

MECHANISM OF ACTION

  • inhibits cell wall synthesis

INDICATIONS

  • empiric treatment for severe sepsis
  • Antimicrobial cover – aerobic and anaerobic bacteria (excluding MRSA, Enterococcus faecium, Stenotrophomonas and many Pseudomonas)
  • specific treatment for melioidosis and Acinetobacter

PHARMACEUTICS

  • water soluble powder for reconstitution

DOSE

  • up to 40mg/kg or 2g Q8hrly (dose reduction in renal impairment)

PHARMACOKINETICS

  • Administration – only IV
  • Distribution – protein binding 2%
  • Metabolism – no active metabolites
  • Elimination – 70% unchanged in urine, t1/2 = 1 hr

ADVERSE EFFECTS

  • rare
  • overgrowth of non-susceptible organisms
  • occasional haematological, gastrointestinal and hepatic adverse effects

CCC Pharmacology Series

Critical Care

Compendium

Chris is an Intensivist and ECMO specialist at The Alfred ICU, where he is Deputy Director (Education). He is a Clinical Adjunct Associate Professor at Monash University, the Lead for the  Clinician Educator Incubator programme, and a CICM First Part Examiner.

He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives. He was one of the founders of the FOAM movement (Free Open-Access Medical education) has been recognised for his contributions to education with awards from ANZICS, ANZAHPE, and ACEM.

His one great achievement is being the father of three amazing children.

On Bluesky, he is @precordialthump.bsky.social and on the site that Elon has screwed up, he is @precordialthump.

| INTENSIVE | RAGE | Resuscitology | SMACC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.